21st April 2016, Newcastle upon Tyne, UK
QuantuMDx, a multinational life sciences tools and technology developer based in Newcastle upon Tyne, were last night awarded the prestigious Medilink UK award for Innovation in recognition of the company’s ground-breaking work revolutionising point-of-care diagnostics and global health surveillance with their technologies Q-POC™ and The Internet of Life™.
Chief Operating Officer Sam Whitehouse PhD and Business Development Manager Jonathan Peat PhD were presented with the award in recognition of the impact Q-POC™ and the Internet of Life™ will have on healthcare systems globally.
Q-POC™ is a handheld molecular diagnostic device that will deliver referral standard results, at the point-of-care in under 15 minutes. It is operated simply and without the need for a stable power source. It will analyse the DNA of disease-causing pathogens to give a diagnostic result, including identifying drug resistance, a process which traditionally takes days, or even weeks. With the ability to carry out analysis on samples such as blood, spit or even tumour tissue, the device will become a powerful tool in the fight against diseases like malaria, tuberculosis and common STIs.
By creating a global network of Q-POC™ devices, called the Internet of Life™, we will be able to track the spread of these diseases and their drug sensitivity, in real-time and mobilise resources to contain these threats before they spread.
CSO and Inventor of Q-POC™ Jonathan O’Halloran commented “Q-POC™ and the Internet of Life™ have the potential to save millions of lives, to gain recognition for their potential impact with this national award is humbling. The Internet of Life™ is possible due to the low cost, fast and portable Q-POC™ device that is set to revolutionise diagnostics and disease surveillance globally. It is thrilling to be building such a profoundly important network that started life as a simple idea as I was suffering from flu over 10 years ago on a flight from LA to Singapore.”
CEO Elaine Warburton said “Q-POC™ and the Internet of Life™ are truly innovative technologies. Not only will they make gold standard diagnostics affordable and accessible to billions of people globally, but they will give Doctors and Nurses the ability to quickly diagnose and treat their patients, giving them more time to focus on seriously ill patients. Ultimately allowing the NHS and other healthcare systems around the world to streamline and simplify their workloads, as samples will not have to be sent to centralized labs and follow up appointments to deliver results will not be needed.”
Dr Whitehouse added “We pride ourselves on creating truly innovative and disruptive technologies, to have our achievements recognised at a national level is a testament to the technologies we’re developing and the fantastic team we have at QuantuMDx.”
Gary Stapleton, Medilink UK Chairman, said: “The Medilink UK Awards are a tremendous showcase of the very best of our sector and it is wonderful to once again celebrate this with our regional awards winners.
“I am continually impressed by the tremendous strides made across the UK Life Sciences sector and I would like to personally congratulate all the Medilink UK Awards winners and nominated organisations for their exceptional work during the past year.”
QuantuMDx are members of Medilink, a national health technology business support organisation, with a strong track record in increasing the viability of manufacturers, service providers, designers, OEMs and suppliers of medical technology.
An image of the award winners can be downloaded from here.
For press enquiries please contact:
Lucy Harvey, Marketing Officer, QuantuMDx Group on 0870 803 1234 or firstname.lastname@example.org
General QuantuMDx imagery can be found here.
About QuantuMDx Group
QuantuMDx Group is a multinational technology developer headquartered in the United Kingdom, with operations and partners in the United States, Asia, Europe and Africa.
The company’s flagship product Q-POC’s superior testing capabilities will bring the power of precision medicine to health professionals globally, enabling immediate detection of antimicrobial resistance and subsequent ‘right first time prescribing’.
QuantuMDx was co-founded by CEO Elaine Warburton OBE, inventor and CSO Jonathan O’Halloran and CFO Julian Warburton. Fellow Board members include CMO Professor Sir John Burn, COO Dr Sam Whitehouse and President of QuantuMDx USA Paul Fitzpatrick. Prof Sanjeev Krishna chairs the Infectious Disease Advisory Committee.
QuantuMDx is a privately owned company with a strong commercial and humanitarian focus.